Abstract
Recent advances in the field of steroid hormone receptors have opened up new possibilities to individualize the treatment of patients with malignancies in hormone-dependent tissues. Examples of tumours where steroid receptor assays have been shown to be or may be of value for planning of therapy are breast, prostatic and endometrial carcinoma and leukaemia. This article focuses on the first two cancer forms.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
